Literature DB >> 2577120

Adenosine A1 receptors inhibit both adenylate cyclase activity and TRH-activated Ca2+ channels by a pertussis toxin-sensitive mechanism in GH3 cells.

D M Cooper1, K K Caldwell, C L Boyajian, D W Petcoff, W Schlegel.   

Abstract

The present study has examined the effects of adenosine A1 receptors on second messenger processes in GH3 cells. A1 receptors are present which are shown to inhibit adenylate cyclase in a GTP-requiring manner. Hormone (VIP) stimulation is also absolutely required for the observation of inhibition. Adenosine A1 receptor analogues also inhibit TRH-stimulated [Ca2+]i-mobilization in GH3 cells. Both effects of the adenosine receptor agonists are apparently mediated by pertussis toxin substrates, of which there are two--41,000 and 40,000 daltons respectively--in these cells. Somatostatin exerts analogous effects to the adenosine agonists in GH3 cells. Thus it may turn out that a general property of 'cyclase inhibitory receptors' is also to inhibit [Ca2+]i-mobilization in the same cells, when such mechanisms are present.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577120     DOI: 10.1016/0898-6568(89)90023-5

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  3 in total

1.  A-type potassium current modulated by A1 adenosine receptor in frog melanotrophs.

Authors:  Y A Mei; E Louiset; H Vaudry; L Cazin
Journal:  J Physiol       Date:  1995-12-01       Impact factor: 5.182

2.  Inhibitory effect of adenosine on electrical activity of frog melanotrophs mediated through A1 purinergic receptors.

Authors:  Y A Mei; H Vaudry; L Cazin
Journal:  J Physiol       Date:  1994-12-01       Impact factor: 5.182

3.  Adenosine receptors in rat basophilic leukaemia cells: transductional mechanisms and effects on 5-hydroxytryptamine release.

Authors:  M P Abbracchio; A M Paoletti; A Luini; F Cattabeni; M A De Matteis
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.